Insulin cost remains 'catastrophic' for millions of Americans, despite Inflation Reduction Act capping Medicare copay at $35 | The Markets Café
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
Tuesday, March 21, 2023
No Result
View All Result
Subscribe
  • Login
The Markets Café
en English
zh-CN 简体中文en Englishfr Françaisde Deutschhi हिन्दीit Italianoja 日本語pt Portuguêsru Русскийes Españoltr Türkçe
  • News
  • Politics
  • Markets
    • Stocks
    • Futures
    • Commodities
  • Crypto
    • News
    • Markets
    • NFT
    • DeFi
    • Explained
  • Economy
  • Finance
  • Investing
  • Forex
  • Real Estate
  • Tech
  • VideosHOT
  • Community
  • Charts
  • News
  • Politics
  • Markets
    • Stocks
    • Futures
    • Commodities
  • Crypto
    • News
    • Markets
    • NFT
    • DeFi
    • Explained
  • Economy
  • Finance
  • Investing
  • Forex
  • Real Estate
  • Tech
  • VideosHOT
  • Community
  • Charts
No Result
View All Result
The Markets Café
No Result
View All Result
  • News
  • Politics
  • Markets
  • Crypto
  • Economy
  • Finance
  • Forex
  • Investing
  • Tech
  • Videos
  • Community
Home Economy

Insulin cost remains ‘catastrophic’ for millions of Americans, despite Inflation Reduction Act capping Medicare copay at $35

by Press Room
August 12, 2022
in Economy
102 1
A A
0
21
SHARES
687
VIEWS
FacebookTwitter

The Inflation Reduction Act of 2022 was poised to pass in the House of Representatives on Friday, after clearing the Senate the weekend before. The good news for millions of seniors on Medicare is that the bill caps out-of-pocket drug costs at $2,000 a year, including a $35 price cap on insulin copays. Considering one in three Medicare beneficiaries has diabetes, and more than 3.3 million of them use insulin, this cap can ease the financial burden of diabetes treatment for millions of people.

But 43 Republicans in the Senate blocked this $35 insulin copay cap from extending to patients on private insurance. Which means that millions more Americans will still struggle to afford a treatment that is essential to staying alive. 

Everyone needs insulin to survive, as this hormone secreted by the pancreas regulates the amount of sugar in the blood. But people who are not creating enough insulin develop diabetes, and often need to inject themselves with insulin to help their bodies break down sugar and create energy. More than 37.3 million Americans have diabetes (or 11.3% of the U.S. population), according to the American Diabetes Association, and 8.4 million Americans rely on taking insulin. 

So what happens when someone does not get enough insulin into their body? Severe hyperglycemia (aka high blood sugar) sets in, which can lead to diabetic ketoacidosis (DKA), meaning the body begins to break down fats for energy instead of sugars. This leads to an excessive amount of acids called ketones building up in the bloodstream and urine. Untreated, it leads to death.

“14% of Americans who rely on insulin face ‘catastrophic’ spending on it, meaning at least 40% of their income after food and housing goes toward insulin. ”

Problem is, a standard vial of insulin now runs between $175 and $300 in the U.S., with some running up to $1,000 — despite costing less than $10 to produce — and the average patient needs about two vials a month. So as the price of insulin has tripled in the U.S. over the past decade, it’s not surprising that a recent Yale study found 14% of Americans who rely on insulin face “catastrophic” spending on it, meaning at least 40% of their income after food and housing goes toward insulin. And this estimate, which covered costs in 2017 and 2018, didn’t even include other diabetes-related costs like glucose monitors, insulin pumps and other medications. Insulin has become so expensive that some people are rationing or skipping their doses — sometimes with fatal results. 

“Insulin is too expensive for too many people with diabetes. We appreciate the Senate approving copay cap for seniors, but disappointed 43 senators opposed making insulin affordable for those with private insurance,” Dr. Robert Gabbay, the American Diabetes Association’s chief scientist and medical officer, said in a statement after the Senate vote. “We stand ready to work with Congress to make insulin affordable for all Americans who need it.”  

And it’s not just diabetics affected by insulin costs. Although insulin is familiar to most people as something diabetics must take, it is also used in cancer treatment, organ preservation, managing septic shock and other critical illnesses in intensive care units.

While many measures in the Inflation Reduction Act have made headlines, the insulin cap became a buzzworthy topic, likely because it impacts so many people. It has led “insulin” to trend on Twitter since the Senate vote. Many called out Republicans who voted against capping the insulin copay on private insurance, or some people shared how much they are spending on insulin each month. 

This could indeed be a hot-button issue in the November midterms. In the week running up to the House vote on the bill, Google searches for “insulin prices” spiked 800% in the U.S., and Americans looking up “insulin” were also googling “voting” in the past week. What’s more, “$35 cap on insulin” and “insulin cap vote” were breakout searches over the past week.  

So why is insulin so expensive when it takes just dollars to produce? Part of the problem is “evergreening,” which is when drug companies extend the life of their patents by making incremental improvements to their products, such as changing the delivery system of insulin by using insulin pens instead of vials. When patents are extended, it discourages the development of cheaper, generic drugs, and the patent-holders with exclusive rights to their insulin can charge whatever the market will bear. Add in supply chain challenges, and prices have spiked. 

So what happens next? And what can people do if they can’t afford their insulin?

Senate Majority Leader Chuck Schumer, a New York Democrat, said Monday that he plans to bring a $35 cap on insulin copays back up for a vote this fall. “We’re going to come back and make them vote on that again,” he said. Earlier this year, a bipartisan insulin measure from Sens. Jeanne Shaheen, a New Hampshire Democrat, and Maine Republican Susan Collins, to cap the cost of insulin at $35 also stalled after failing to get GOP support; it’s unclear whether Schumer’s plan would work with this bipartisan effort.

And some states and drugmakers
PJP,
+1.30%
are also working to bring down the cost of insulin. Civica Rx plans to produce and sell generic insulin to consumers at less than $30 per vial, and under $55 for a box of five pen cartridges. And California Gov. Gavin Newsom recently approved a budget allocating $100 million for the state to start making its own low-cost insulin.

What’s more, 22 states and the District of Columbia have capped copayments on insulin and diabetes supplies, the American Diabetes Association shared. But there’s a big “but” here — many state healthcare laws and state caps don’t apply to patients on job-based plans, aka self-funded plans or self-insured plans –– which is what 61% of workers with health insurance were covered by in 2016, according to the Kaiser Family Foundation. So even in states with caps on diabetes treatments, patients may still end up bearing the brunt of the expense by themselves.

The American Diabetes Association has also consolidated resources for anyone struggling to pay for insulin and other diabetes treatments at insulinhelp.org.

And this is what else the Inflation Reduction Act does for climate, drug prices and taxes.

Read the full article here

Related Articles

Economy

Dodge resurrects controversial Challenger SRT Demon for final year of V8 muscle cars

March 21, 2023
Economy

Feds mull unlimited deposit guarantees if bank crisis worsens: report

March 21, 2023
Economy

Amazon’s post-Bezos experiment hasn’t gone exactly as planned

March 21, 2023
Economy

‘Ted Lasso’ star Jason Sudeikis talks mental health at White House, calls for taking care of each other

March 21, 2023
Economy

President Biden has confidence in Fed chief Powell, White House says

March 21, 2023
Economy

DeSantis comments on possible Trump arrest over ‘hush money’ payments

March 20, 2023

About Us

The Markets Café

The Markets Cafe is your one stope Finance, Politics and bussines news website, follow us to get the latest news and updates from around the world.

Sections

  • Commodities
  • Crypto Markets
  • Crypto News
  • DeFi
  • Economy
  • Explained
  • Finance
  • Forex
  • Futures
  • Investing
  • Markets
  • News
  • NFT
  • Politics
  • Real Estate
  • Stocks
  • Tech
  • Videos

Site Links

  • Contact
  • Advertise
  • DMCA
  • Submit Article
  • Forum
  • Site info
  • Newsletter

Newsletter

THE MOST IMPORTANT FINANCE NEWS AND EVENTS OF THE DAY

Subscribe to our mailing list to receives daily updates direct to your inbox!

  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact

© 2022 The Markets Café - All rights reserved.

No Result
View All Result
  • News
  • Politics
  • Markets
    • Stocks
    • Futures
    • Commodities
  • Crypto
    • News
    • Markets
    • NFT
    • DeFi
    • Explained
  • Economy
  • Finance
  • Investing
  • Forex
  • Real Estate
  • Tech
  • Videos
  • Community
  • Charts

© 2022 The Markets Café - All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.